Biocon's Pertuzumab Biosimilar Receives Positive EMA CHMP Recommendation

Biocon Biologics, a wholly owned Biocon subsidiary, received a positive CHMP opinion recommending EMA marketing authorization for Pebrilzo, its pertuzumab biosimilar. The recommendation advances the product toward European commercialization and could expand Biocon Biologics' oncology biosimilar portfolio, subject to final European Commission approval.